← Leaderboards
Bradford Alan Woodworth
University Of Alabama At Birmingham
$3,946,767
Attributed
$3,946,767
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $608.2K · FY2011–24$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,946,767 · 4
By mechanism
R01$1,735,567 · 1
P30$1,138,557 · 1
K08$667,980 · 1
R21$404,663 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Vivian Y Lin$76,070
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCystic Fibrosis Transmembrane Conductance RegulatorFunctional DisorderCystic FibrosisNoseIn VitroViscosityClinical TrialsMucociliary ClearanceMucous Body SubstanceNovel TherapeuticsEpithelialMorbidity - Disease RateIon TransportLaboratoriesEpitheliumAnionsPathway InteractionsPatch ClampResponseMediatingNasal EpitheliumCellsInflammation
Grant awards (17)
A Ginsenoside TMEM16A Potentiator for Cystic Fibrosis$181,913
R21 · FY2024 · AT · contact PI
A Ginsenoside TMEM16A Potentiator for Cystic Fibrosis$222,750
R21 · FY2023 · AT · contact PI
Core A: Cell Model and Evaluation Core$241,719
P30 · FY2022 · DK · contact PI
Core A: Cell Model and Evaluation Core$241,719
P30 · FY2021 · DK · contact PI
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis$318,014
R01 · FY2020 · HL · contact PI
Core A: Cell Model and Evaluation Core$171,681
P30 · FY2020 · DK · contact PI
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis$318,014
R01 · FY2019 · HL · contact PI
Core A: Cell Model and Evaluation Core$241,719
P30 · FY2019 · DK · contact PI
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis$366,513
R01 · FY2018 · HL · contact PI
Core A: Cell Model and Evaluation Core$241,719
P30 · FY2018 · DK · contact PI
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis$366,513
R01 · FY2017 · HL · contact PI
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis$366,513
R01 · FY2016 · HL · contact PI
Chloride secretagogues for acquired CFTR dysfunction in chronic rhinosinusitis$133,596
K08 · FY2015 · HL · contact PI
Chloride secretagogues for acquired CFTR dysfunction in chronic rhinosinusitis$133,596
K08 · FY2014 · HL · contact PI
Chloride secretagogues for acquired CFTR dysfunction in chronic rhinosinusitis$133,596
K08 · FY2013 · HL · contact PI
Chloride secretagogues for acquired CFTR dysfunction in chronic rhinosinusitis$133,596
K08 · FY2012 · HL · contact PI
Chloride secretagogues for acquired CFTR dysfunction in chronic rhinosinusitis$133,596
K08 · FY2011 · HL · contact PI